Navigation Links
TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
Date:9/30/2010

JERUSALEM, BOTHELL, WA and VANCOUVER, Sept. 30 /PRNewswire-FirstCall/ - Teva Pharmaceuticals Industries Ltd. (NASDAQ: TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC). The SYNERGY trial is the second of three Phase 3 trials to be initiated under a global collaboration and license agreement between Teva and OncoGenex to develop and commercialize custirsen.

The SYNERGY trial is a randomized, controlled, global Phase 3 trial to be conducted in approximately 125 cancer centers and with designated recruitment of 800 men with metastatic CRPC who have disease progression and require first-line docetaxel/prednisone chemotherapy. Patients will be randomized to receive treatment with either docetaxel/prednisone plus custirsen or with docetaxel/prednisone alone. The primary endpoint of the trial is to determine whether overall survival is longer in the custirsen treatment arm. The trial design is based on the Phase 2 trial results demonstrating clinical benefits of custirsen treatment with a hazard ratio consistent with a 49% reduction in the rate of death and a median overall survival of 23.8 months compared to 16.9 months.

The initiation of SATURN, the first Phase 3 trial with custirsen was announced by Teva and OncoGenex in June 2010. This global Phase 3 trial will enrol patients with metastatic CRPC who have previously responded to first line docetaxel/prednisone treatment but subsequently have disease progression that involves pain despite opioid usage.

"The prostate cancer landscape is rapidly evolving with the introduction of new therapies to improve patient outcomes." said Dr.
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
2. OncoGenex Reports Second Quarter Financial Results
3. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
4. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
7. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
8. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
9. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
10. OncoGenex Reports Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... June 03, 2015 Marktech Optoelectronics is ... Photodiodes. Marktech APD’s have an internal gain mechanism, fast ... the near infrared region. These APD’s are recommended for ... is needed to overcome high pre-amp noise. In addition, ... and are ideal for extreme low-level light detection and ...
(Date:6/2/2015)... , June 2, 2015 TapImmune, Inc. (OTCQB: ... institutional investors have reached an agreement whereby the institutional ... term warrants to provide the Company up to $4.93M ... effective S-1 registration statement. Under the restructured terms and ... call additional warrants which could result in a larger ...
(Date:6/2/2015)... NEW YORK , Jun. 02, 2015 /PRNewswire/ ... "Company"), a diversified life sciences company with interests ... a proprietary synthetic biology platform technology, today announced ... to Typenex Co-Investment, LLC ("Typenex") in exchange for ... January 16, 2015, the Company and Typenex entered ...
(Date:6/2/2015)... June 02, 2015 Cirrascale ... blade-based and rackmount computing and storage infrastructure for ... launch of its high density scale-out, two-in-one video ... Slipstream™ RM1622D . The high density, two-in-one system ... product family with Intel® Iris™ Pro graphics P6300 ...
Breaking Biology Technology:Marktech Introduces New Line of APDs 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 2Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 3Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 4Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3
... NimbleGen Systems , a manufacturer of gene chips for ... offering of stock following its acquisition by Roche , ... to raise $75 million in the IPO, but under the ... Roche will acquire 100 percent of the privately held NimbleGen ...
... - Paul Schneider, a director for the Green Bay-based ... to the board of TrafficCast International , a ... National, Schneider is responsible for new business development and ... , ,Schneider is a long-haul trucking company and a ...
... - Madison and 12 other cities will share a ... Energy as part of the DOE's 2007 Solar America ... a $60 million DOE solar energy program announced ... two-year projects that are designed to integrate solar technologies into ...
Cached Biology Technology:NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 2NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 3NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 4
(Date:5/19/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... access publishing program that offers immediate publication followed by ... after publication. Following recent approval by the National Library ... this peer review process will now be listed in ... F1000Research ,s acceptance by the NLM Selections group ...
... Health, science and genetics reporters are invited to register ... Genomics (ACMG) Annual Clinical Genetics Meeting, March 19-23, 2013 ... Whole Genome/Exome Sequencing, the focus of the ACMG Meeting ... in healthcare today and in the future. The conference ...
... A new method of establishing hair and eye colour from ... from ancient human remains, finds a new study published in ... HIrisPlex DNA analysis system was able to reconstruct hair and ... the Polish General Wladyslaw Sikorski (1881 to 1943) confirming his ...
Cached Biology News:
...
... a powerful tool for sample purification in ... DNA/RNA or protein purification as well as ... automated on the Genesis Series of instruments ... combination with the RoMa arm and Tecans ...
... filters suitable for use in the Microsart e.motion ... each filter, in a specially designed individual package ... of the band of membrane filter units ensures ... shape of the sealed band guarantees uniform dispensing ...
...
Biology Products: